Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 14Myelodysplastic Syndromes 7Myeloproliferative Disorders 3Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myelomonocytic, Chronic 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1GATA2 Deficiency 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1BRCA1 Mutation 1Anemia, Refractory, with Excess of Blasts 1Allogeneic Stem Cell Transplantation 1

Interventions

Specimen Handling 4Nivolumab 4avelumab 3Magnetic Resonance Spectroscopy 3Biopsy 3pembrolizumab 2talimogene laherparepvec 1prednylidene 1fludarabine phosphate 1fludarabine 1deltacortene 1decitabine and cedazuridine drug combination 1aldesleukin 1Sirolimus 1Saline Solution 1Radiosurgery 1Prednisone 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1Axitinib 1Antineoplastic Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Merkel Cell × decitabine and cedazuridine drug combination × 30 days × Clear all
NCT07472322 2026-05-29

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

University of Wisconsin, Madison

Phase 1/2 Not yet recruiting
31 enrolled
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡